<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00691600</url>
  </required_header>
  <id_info>
    <org_study_id>H-18758</org_study_id>
    <nct_id>NCT00691600</nct_id>
  </id_info>
  <brief_title>Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage</brief_title>
  <official_title>Phase 3 Study Comparing Bactrim to Placebo in the Management of Abscesses &lt; 5cm in the Pediatric Population.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare rates of cure of abscesses with and without antibiotic
      treatment after incision and drainage. The purpose of this study is to compare successful
      rates of cure of abscesses less than 5 cm with antibiotic (oral TMP/SMX) versus
      non-antibiotic treatment after incision and drainage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized controlled trial of antibiotic treatment versus placebo after
      incision and drainage of skin and soft tissue abscesses less than 5 cm in pediatric patients.
      Eligible patients whose parents/guardians consented them to enrollment were randomized to
      receive one of two interventions: oral trimethoprim/sulfamethoxazole (TMP/SMX) or placebo
      after incision and drainage. Every attempt was made to make the placebo capsules and
      suspensions appear in all aspects like the true drug (was done by the investigational
      pharmacy department at our institution). Equal numbers of subjects were randomized at the
      outset to both study groups. Randomization, also done by our investigational pharmacy
      department, was done in blocks of 20. Patients were followed up in our emergency center at 24
      to 48 hours to have any packing removed and to have their clinical/wound status assessed.
      They were not charged for this visit, and their valet parking was validated. If an individual
      patient, or an individual patient's wound, was felt to be not improving adequately, that
      patient was started on formal antibiotic therapy at the treating attending physician's
      discretion.

      Primary outcome:

      1. Abscess resolution by parental report 7-10 days after incision and drainage

      Secondary outcomes:

        1. Admission to the hospital because of worsening infection

        2. Receipt of antibiotics (placebo arm) or change in antibiotics (antibiotic arm)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Abscess Resolution</measure>
    <time_frame>10 days</time_frame>
    <description>Outcomes will be measured by resolution of size, tenderness, and induration with erythema by parental report 7 - 10 days after initial visit to the Emergency Center</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Requiring Admission for Failure of Abscess Resolution</measure>
    <time_frame>10 days</time_frame>
    <description>Percentage of patients requiring admission to Texas Children's or another hospital within 10 days of incision and drainage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Requiring New or Modified Antibiotics for Failure of Abscess to Resolve</measure>
    <time_frame>10 days</time_frame>
    <description>For the antibiotic arm, we determined if the child was prescribed a different antibiotic.
For the placebo arm, we determined if the child received a prescription for an antibiotic at a subsequent visit (e.g., in the emergency department, by their pediatrician, etc) within 10 days of incision and drainage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Abscess</condition>
  <arm_group>
    <arm_group_label>oral trimethoprim/sulfamethoxazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects with abscesses less than 5cm will be randomized to either study med or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo after incision and drainage of abscess less than 5 cm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral trimethoprim/sulfamethoxazole</intervention_name>
    <description>80 mg caps or 8 mg/ml suspension every 12 hours for 10 days</description>
    <arm_group_label>oral trimethoprim/sulfamethoxazole</arm_group_label>
    <other_name>TMP/SMX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo caps or suspension every 12 hours for 10 days</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Placebo caps</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.) Abscess &lt; 5 cm (&lt; 5 cm of induration and fluctuance) requiring incision and drainage
        2.) Age &gt; 90 days and &lt; 18 years 3.) Abscess on the trunk, scalp, extremities, or axillae

        Exclusion Criteria:

          1. Multiple abscesses

          2. Abscess located on the hands, face, or perineum

          3. Abscess as a result of a bite wound

          4. Immunocompromised patient - i.e., diabetes, sickle cell, chronic steroid therapy (&gt; 10
             days), etc.

          5. Previously failed 48 hours or greater therapy on any antibiotic regimen 6.) Drug
             allergy to TMP/SMX

        7.) Fever &gt; or = 102.2 degrees Fahrenheit in the previous 24 hours 8.) Systemic symptoms on
        presentation - i.e., nausea , vomiting, persistent tachycardia, hypotension, diaphoresis,
        etc.

        9.) Signs /symptoms of another infection or illness - i.e., influenza, croup, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>90 Days</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Cruz, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2008</study_first_posted>
  <results_first_submitted>August 21, 2017</results_first_submitted>
  <results_first_submitted_qc>June 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2020</results_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Andrea Cruz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>abscess</keyword>
  <keyword>Abscesses in the pediatric emergency population</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abscess</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Antibiotic Arm</title>
          <description>subjects with abscesses less than 5cm will be randomized to oral trimethoprim/sulfamethoxazole: 80 mg caps or 8 mg/ml suspension every 12 hours for 10 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo Arm</title>
          <description>Patients with abscesses &lt; 5cm randomized to placebo tablets or suspension twice a day for 10 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention to treat</population>
      <group_list>
        <group group_id="B1">
          <title>Oral Trimethoprim/Sulfamethoxazole</title>
          <description>subjects with abscesses less than 5cm will be randomized to study medication, oral trimethoprim/sulfamethoxazole:
80 mg caps or 8 mg/ml suspension every 12 hours for 10 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo After Incision and Drainage</title>
          <description>Patients with abscesses less than 5cm will be randomized to receive placebo.
Placebo: Placebo capsules every 12 hours for 10 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abscess Resolution</title>
        <description>Outcomes will be measured by resolution of size, tenderness, and induration with erythema by parental report 7 - 10 days after initial visit to the Emergency Center</description>
        <time_frame>10 days</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Antibiotic Arm</title>
            <description>oral trimethoprim/sulfamethoxazole: 80 mg caps or 8 mg/ml suspension every 12 hours for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Receipt of placebo in either capsule or suspension formulation twice daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abscess Resolution</title>
          <description>Outcomes will be measured by resolution of size, tenderness, and induration with erythema by parental report 7 - 10 days after initial visit to the Emergency Center</description>
          <population>Intention to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Requiring Admission for Failure of Abscess Resolution</title>
        <description>Percentage of patients requiring admission to Texas Children's or another hospital within 10 days of incision and drainage</description>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antibiotic Arm</title>
            <description>oral trimethoprim/sulfamethoxazole: 80 mg caps or 8 mg/ml suspension every 12 hours for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Receipt of placebo in either capsule or suspension formulation twice daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring Admission for Failure of Abscess Resolution</title>
          <description>Percentage of patients requiring admission to Texas Children's or another hospital within 10 days of incision and drainage</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Requiring New or Modified Antibiotics for Failure of Abscess to Resolve</title>
        <description>For the antibiotic arm, we determined if the child was prescribed a different antibiotic.
For the placebo arm, we determined if the child received a prescription for an antibiotic at a subsequent visit (e.g., in the emergency department, by their pediatrician, etc) within 10 days of incision and drainage</description>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antibiotic Arm</title>
            <description>oral trimethoprim/sulfamethoxazole: 80 mg caps or 8 mg/ml suspension every 12 hours for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Receipt of placebo in either capsule or suspension formulation twice daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring New or Modified Antibiotics for Failure of Abscess to Resolve</title>
          <description>For the antibiotic arm, we determined if the child was prescribed a different antibiotic.
For the placebo arm, we determined if the child received a prescription for an antibiotic at a subsequent visit (e.g., in the emergency department, by their pediatrician, etc) within 10 days of incision and drainage</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Antibiotic Arm</title>
          <description>subjects with abscesses less than 5cm who received oral trimethoprim/sulfamethoxazole: 80 mg caps or 8 mg/ml suspension every 12 hours for 10 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo Arm</title>
          <description>subjects with abscesses less than 5cm who received placebo capsules or suspension every 12 hours for 10 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrea T. Cruz, MD, MPH</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>832-824-5582</phone>
      <email>acruz@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

